Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide phase 2b study in adults with precirrhotic nonalcoholic steatohepatitis
jRCT2031230187Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, randomised, double-blind trial of efinopegdutide and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) (5 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with nonalcoholic steatohepatitis resolution without worsening of fibrosis at Week 52, Percentage of participants who experienced an adverse event and 1 more. Started Jul 2023; status: completed.
02
Drugs
efinopegdutidesemaglutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031230187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230187.